NADMED raises €3.5M to bring NAD tests to international markets, advancing personalized treatment options
Finnish biotech company NADMED has developed the first test to measure all four bodily forms of vitamin B3, called NADs, and glutathiones directly from fresh blood in hours, with the highest accuracy on the market. NADMED provides crucial information on vitamin B3 deficiencies, which have been linked to degenerative age-related diseases such as metabolic diseases, cancer, neurodegenerative and heart diseases.HELSINKI, Finland (August 22nd, 2024) Finnish biotech company NADMED has closed a €3.5M series A round to fund its entry into the U.S. and other international